Seebri Neohaler (glycopyrrolate) Inhalation Powder
Seebri Neohaler (glycopyrrolate) inhalation powder is an anticholinergic medication that works to inhibit the effects of acetylcholine and provide long-term maintenance treatment for COPD. It is also known as a long-acting antimuscarinic agent (LAMA). Blocking acetylcholine can relax the muscles around the lungs and airways, decreasing common symptoms of COPD, such as wheezing, chest tightness, and shortness of breath. The Seebri Neohaler is indicated for adults with COPD.
What are the ingredients in Seebri Neohaler?
The active ingredient in Seebri Neohaler is glycopyrrolate, the anticholinergic medication.
How does Seebri Neohaler work?
The Seebri Neohaler is an anticholinergic medication, meaning it works to inhibit acetylcholine. Acetylcholine acts in nerve cells that control the involuntary muscle movements of the lungs, urinary tract, and gastrointestinal tract, among others. Acetylcholine is a chemical messenger (neurotransmitter) that passes signals from one nerve cell to another, instructing the body on how its muscles should work. By blocking this messenger, the Seebri Neohaler can allow the muscles around the lungs and airways to relax. When these muscles are relaxed, common COPD symptoms like chest tightness, shortness of breath, and wheezing can be improved.
What are the possible side effects of Seebri Neohaler?
Throughout multiple clinical trials evaluating the safety and efficacy of Seebri Neohaler, the most common side effects were upper respiratory tract infections, runny nose, urinary tract infection and sore throat. There is a possibility of experiencing an allergic reaction when using the Seebri Neohaler. Alert your doctor immediately, or contact your local emergency department if you have any signs of reaction, including:
- Swelling of tongue, lips and/or face
- Trouble breathing or swallowing
If you notice a sudden shortness of breath right after using the medication, it is important to alert your doctor immediately or contact your local emergency department, as this could be life-threatening.
Other serious side effects include developing new or worsened eye issues, such as acute narrow-angle glaucoma, as well as developing new or worsening urinary retention difficulties. Alert your doctor if you notice any of the following symptoms:
- Eye pain or discomfort
- Nausea or vomiting
- Red eyes
- Seeing bright colors or halos around lights
- Blurred vision
- Painful urination
- Urinating frequently
- Difficulty urinating including urinating in drips or weak streams
This is not an exhaustive list of all potential side effects of Seebri Neohaler. Talk to your healthcare provider or pharmacist for further information.
Before starting Seebri Neohaler tell your provider about all medical conditions you may have, and treatments you are taking including:
- Kidney problems
- Bladder or Prostate problems
- Eye problems such as glaucoma
- Other medical conditions
- If you are pregnant or planning to become pregnant
- If you are breastfeeding or planning to breastfeed
- Allergic to any of the ingredients in the Seebri Neohaler, as well as any ingredients in other medications or foods
- If you are taking other anticholinergic medications, as these can work in additive ways to one another and cause serious problems
- If you are taking any over-the-counter medications, vitamins, or herbal supplements
Do not stop taking the Seebri Neohaler or other COPD medications without talking to your healthcare provider first.
The Seebri Neohaler should be taken twice daily, with one capsule taken in the morning, and another capsule in the evening. The capsules contain 15.6 mcg of glycopyrrolate powder, and no more than one capsule should be taken at a time. Use only as your provider directs. Do not take more than twice a day. The inhaler can be opened after use, and if no powder is left in the capsule, the full dose has been administered.
For additional information on Seebri Neohaler, read the full prescribing information here.
- Seebri Neohaler Prescribing Information. Novartis Pharmaceuticals Corporation. Jan 2017. Available from: https://www.seebri.us/Seebri-Prescribing-Information.pdf